Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Latest News on CMMB

Dec 3, 2024, 7:00 AM EST - 6 weeks ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 19, 2024, 7:00 AM EST - 2 months ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Aug 21, 2024, 7:00 AM EDT - 5 months ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 5 months ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 6 months ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 6 months ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 7:38 AM EDT - 6 months ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 6 months ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 8 months ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 8 months ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 9 months ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 10 months ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 11 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 5, 2024, 7:00 AM EST - 11 months ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 11 months ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 1 year ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 1 year ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 1 year ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:15 PM EST - 1 year ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Jun 28, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Jun 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

Jun 21, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Jun 2, 2023, 9:00 AM EDT - 1 year ago

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

May 14, 2023, 11:20 AM EDT - 1 year ago

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

May 11, 2023, 6:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

Apr 12, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

Mar 29, 2023, 8:30 AM EDT - 1 year ago

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

Mar 17, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

Mar 6, 2023, 7:00 AM EST - 2 years ago

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 8:25 AM EST - 2 years ago

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

Feb 21, 2023, 7:00 AM EST - 2 years ago

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

Jan 3, 2023, 7:00 AM EST - 2 years ago

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

Dec 21, 2022, 7:00 AM EST - 2 years ago

Market Cap	28.00M
Revenue (ttm)	0.00
Net Income (ttm)	-24.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,100
Avg Vol	113,066
Day's Range	N/A - N/A
Shares Out	14.36M
Stochastic %K	45%
Beta	0.65
Analysts	Strong Sell
Price Target	$8.00